WCLC 2025 - Posters & ePosters-EP.06.09 Integrated Clinical, Radiological and Molecular Profile of Lung Cancer Patients From an Incidental Nodule Detection Program

EP.06.09 Integrated Clinical, Radiological and Molecular Profile of Lung Cancer Patients From an Incidental Nodule Detection Program

Back to course

Pdf Summary

This study examined the integrated clinical, radiological, and molecular profiles of lung cancer patients diagnosed through an incidental nodule detection program at a tertiary center in Brazil between January 2023 and December 2024. A total of 74 lung cancer cases were analyzed, with 72 detected via the incidental nodule program. Molecular or immunohistochemical data were available for 61 patients, of whom 83.6% had adenocarcinoma histology. Among 36 patients undergoing molecular testing, 83.7% were adenocarcinoma.<br /><br />Key findings highlighted incomplete molecular testing limited comprehensive biomarker assessment. EGFR mutations were more frequent among women and those without tobacco exposure, showing an inverted distribution in early-stage disease. Mutations (EGFR, ALK, KRAS, ROS1) were associated predominately with non-mucinous, acinar, and lepidic histological patterns. No BRAF mutations or microsatellite instability were detected in the cohort. Immunohistochemical analysis revealed most tumors expressed low PD-L1 levels (1%), with intermediate PD-L1 expression more common in acinar and squamous carcinomas.<br /><br />The staging distribution showed 30% stage I, 13% stage II, 14% stage III, and 43% stage IV disease, with a median patient age of 72 years and 56.7% female representation. Among 10 patients tested for EGFR exon 19 deletion, 40% were positive; for exon 21 mutation, 80% were positive.<br /><br />The study underscores the necessity of systematic molecular testing integrated into incidental lung nodule workflows, even in early-stage lung cancer, to fully capture biomarker prevalence and guide personalized treatment strategies. The associations between biomarker profiles and tumor histology suggest potential to refine and customize patient care. Data were updated post-abstract submission and are presented here to enhance understanding of lung cancer molecular epidemiology within incidental detection programs.

Asset Subtitle

Francisco Sarmento Neto

Meta Tag

Speaker Francisco Sarmento Neto

Topic Pathology and Biomarkers

Keywords

lung cancer

incidental nodule detection

molecular testing

adenocarcinoma

EGFR mutations

biomarker assessment

PD-L1 expression

tumor histology

staging distribution

personalized treatment